Immutep: fighting the good fight

Immutep (ASX: IMM) are global leaders in the understanding and development of  immunotherapy drugs for cancer and autoimmune diseases. IMM’s objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for...

Institutions Support Immutep Capital Raising

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to announce it has completed the second tranche of its institutional placement (Placement), details of which were announced to the market on 21 June 2021. The second tranche of the...